CAPR
Capricor Therapeutics, Inc. NASDAQ Listed Feb 13, 2007$29.34
+3.38%
vs $28.38
Mkt Cap $1.4B
52w Low $4.60
80.5% of range
52w High $35.34
50d MA $30.54
200d MA $21.50
P/E (TTM)
-12.7x
EV/EBITDA
1.2x
P/B
4.5x
Debt/Equity
0.1x
ROE
-34.4%
P/FCF
-0.0x
RSI (14)
53.90
ATR (14)
$1.32
Beta
0.48
50d MA
$30.54
200d MA
$21.50
Avg Volume
1.1M
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
10865 Road to the Cure · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.51 | -0.62 | -21.6% | 33.42 | -1.3% | -8.7% | +0.2% | +2.1% | -0.9% | +0.9% | — |
| Nov 10, 2025 | AMC | -0.54 | -0.54 | +0.0% | 5.56 | +5.9% | +11.5% | -5.3% | -1.7% | -2.9% | +1.6% | — |
| Aug 11, 2025 | AMC | -0.48 | -0.57 | -18.8% | 7.82 | +0.4% | +2.8% | +3.2% | -6.3% | +2.3% | -3.3% | — |
| May 13, 2025 | AMC | -0.33 | -0.53 | -60.6% | 7.30 | +6.0% | +5.1% | +24.6% | -1.3% | +9.9% | +6.2% | — |
| Mar 19, 2025 | AMC | -0.31 | -0.16 | +48.4% | 12.22 | +2.8% | +17.5% | -10.4% | +3.3% | +1.5% | -2.2% | — |
| Nov 13, 2024 | AMC | -0.36 | -0.38 | -5.6% | 16.91 | +0.1% | +9.3% | +0.6% | -1.2% | +0.4% | +2.5% | — |
| Aug 7, 2024 | AMC | -0.36 | -0.35 | +2.8% | 3.56 | +12.9% | +9.0% | -3.1% | +4.3% | +0.3% | -2.8% | — |
| May 13, 2024 | AMC | -0.11 | -0.31 | -181.8% | 5.44 | -5.7% | -4.4% | +2.5% | +5.8% | +9.9% | +1.6% | — |
| Feb 29, 2024 | AMC | -0.09 | -0.02 | +77.8% | 4.20 | +5.5% | +8.8% | +2.2% | +6.2% | +4.6% | -2.9% | — |
| Nov 14, 2023 | AMC | -0.29 | -0.25 | +13.8% | 3.01 | -0.3% | +6.6% | -4.0% | -1.3% | -2.3% | -1.7% | — |
| Aug 7, 2023 | AMC | -0.35 | -0.29 | +17.1% | 4.71 | +0.0% | +21.7% | +3.0% | +1.0% | +1.3% | +9.4% | — |
| May 11, 2023 | AMC | -0.32 | -0.31 | +3.1% | 4.11 | -0.7% | -1.9% | +4.0% | +1.2% | +2.6% | +6.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | B. Riley Securities | Maintains | Buy → Buy | — | $33.42 | $33.00 | -1.3% | -8.7% | +0.2% | +2.1% | -0.9% | +0.9% |
| Mar 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $33.42 | $33.00 | -1.3% | -8.7% | +0.2% | +2.1% | -0.9% | +0.9% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.42 | $33.00 | -1.3% | -8.7% | +0.2% | +2.1% | -0.9% | +0.9% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.63 | $32.50 | +6.1% | +9.0% | +0.5% | -0.4% | -8.7% | +0.2% |
| Dec 15 | B. Riley Securities | Maintains | Buy → Buy | — | $26.02 | $25.87 | -0.6% | +2.0% | -2.0% | +0.5% | +0.2% | +6.2% |
| Dec 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $27.38 | $28.30 | +3.4% | +4.7% | -5.2% | -4.3% | +2.0% | -2.0% |
| Dec 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $26.89 | $26.60 | -1.1% | +6.2% | -4.1% | +4.7% | -5.2% | -4.3% |
| Dec 4 | Maxim Group | Maintains | Buy → Buy | — | $29.96 | $28.25 | -5.7% | -15.2% | +5.9% | +6.2% | -4.1% | +4.7% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.36 | $30.00 | +371.7% | +371.1% | -15.2% | +5.9% | +6.2% | -4.1% |
| Nov 12 | Roth Capital | Maintains | Buy → Buy | — | $6.20 | $6.18 | -0.3% | -5.3% | -1.7% | -2.9% | +1.6% | -0.9% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.19 | $6.81 | +10.0% | +5.3% | +8.7% | +4.5% | -2.7% | +8.5% |
| Sep 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.33 | $6.11 | -3.5% | +1.7% | -1.2% | -5.0% | +3.0% | -2.3% |
| Jul 14 | Roth Capital | Maintains | Buy → Buy | — | $7.64 | $7.39 | -3.3% | -3.3% | -2.8% | +0.8% | -1.1% | -3.9% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.40 | $7.00 | -38.6% | -33.0% | -3.3% | -2.8% | +0.8% | -1.1% |
| Jun 25 | Jones Trading | Maintains | Buy → Buy | — | $9.25 | $9.24 | -0.1% | +8.6% | +1.3% | +9.5% | -10.9% | -2.3% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.68 | $7.90 | +2.9% | +20.4% | +8.6% | +1.3% | +9.5% | -10.9% |
| Jun 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.26 | $8.00 | -3.1% | -7.0% | +20.4% | +8.6% | +1.3% | +9.5% |
| Jun 17 | Roth Capital | Maintains | Buy → Buy | — | $12.38 | $12.12 | -2.1% | -1.5% | -2.1% | -30.8% | -7.0% | +20.4% |
| Jun 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.94 | $13.55 | -2.8% | -15.5% | +5.1% | -1.5% | -2.1% | -30.8% |
| May 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.30 | $7.74 | +6.0% | +5.1% | +24.6% | -1.3% | +9.9% | +6.2% |
| Mar 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $12.22 | $12.56 | +2.8% | +17.5% | -10.4% | +3.3% | +1.5% | -2.2% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.22 | $12.56 | +2.8% | +17.5% | -10.4% | +3.3% | +1.5% | -2.2% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.23 | $13.32 | +0.7% | -2.6% | -9.9% | +5.3% | +17.5% | -10.4% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.67 | $15.11 | +10.5% | +0.2% | -7.7% | +7.4% | -5.7% | -3.7% |
| Jan 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.80 | $14.02 | +1.6% | +8.4% | +4.3% | -3.9% | -5.2% | -2.5% |
| Nov 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.91 | $16.92 | +0.1% | +9.3% | +0.6% | -1.2% | +0.4% | +2.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.91 | $16.92 | +0.1% | +9.3% | +0.6% | -1.2% | +0.4% | +2.5% |
| Jul 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.84 | $4.81 | -0.6% | -2.5% | +2.3% | -0.4% | -0.8% | -3.8% |
| May 14 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $5.44 | $5.13 | -5.7% | -4.4% | +2.5% | +5.8% | +9.9% | +1.6% |
| May 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.44 | $5.13 | -5.7% | -4.4% | +2.5% | +5.8% | +9.9% | +1.6% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.44 | $5.13 | -5.7% | -4.4% | +2.5% | +5.8% | +9.9% | +1.6% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.04 | $5.06 | +0.4% | +2.2% | +5.0% | -1.5% | -1.1% | +1.1% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.43 | +5.5% | +8.8% | +2.2% | +6.2% | +4.6% | -2.9% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.90 | $3.10 | +6.9% | -2.1% | +0.0% | +2.1% | -4.1% | +2.5% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.61 | $6.69 | +1.2% | +8.0% | -7.0% | +10.5% | -5.9% | +11.6% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.47 | $4.47 | +0.0% | +2.0% | -4.8% | +3.2% | -1.8% | -2.7% |
| Oct 26 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $5.73 | $5.98 | +4.4% | +6.3% | -5.1% | -3.3% | -0.5% | -2.2% |
| Jan 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.15 | $3.17 | +0.6% | +13.3% | +2.8% | +1.9% | +10.4% | +2.7% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.73 | $3.94 | +5.6% | +9.1% | -2.2% | +3.5% | +1.0% | -4.8% |
| Nov 25 | H.C. Wainwright | Maintains | Buy → Buy | — | $4.03 | $4.00 | -0.7% | +0.0% | +6.5% | -2.1% | -1.0% | -0.5% |
| Nov 25 | Roth Capital | Maintains | Buy → Buy | — | $4.03 | $4.00 | -0.7% | +0.0% | +6.5% | -2.1% | -1.0% | -0.5% |
| Nov 25 | Maxim Group | Maintains | Buy → Buy | — | $4.03 | $4.00 | -0.7% | +0.0% | +6.5% | -2.1% | -1.0% | -0.5% |
| Jul 15 | H.C. Wainwright | Maintains | Buy → Buy | — | $3.22 | $7.15 | +122.0% | +93.5% | -3.7% | -5.0% | -7.9% | +7.4% |
| Jul 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.22 | $7.15 | +122.0% | +93.5% | -3.7% | -5.0% | -7.9% | +7.4% |
| Dec 31 | H.C. Wainwright | Maintains | Buy → Buy | — | $3.70 | $3.70 | +0.0% | +10.8% | +22.0% | -4.0% | +6.2% | +21.6% |
| Dec 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.70 | $3.70 | +0.0% | +10.8% | +22.0% | -4.0% | +6.2% | +21.6% |
| May 16 | Maxim Group | Maintains | Buy → Buy | — | $13.00 | $13.40 | +3.1% | +2.3% | +2.3% | +1.5% | +0.0% | +0.0% |
| Jun 15 | Roth Capital | Maintains | Buy → Buy | — | $35.40 | $35.40 | +0.0% | +17.2% | +14.5% | -6.1% | -0.7% | -2.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Sell | 25,000 | $31.70 | $793K | 8,223 | -1.61% | +5.00% |
| May 1, 2026 | Krasney Karen | EVP, GENERAL COUNSEL | Sell | 25,000 | $31.70 | $793K | 30,547 | -1.61% | +5.00% |
8-K · 2.02
!! High
Capricor Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K
Unknown — 8-K Filing
Capricor's deramiocel BLA submission for Duchenne muscular dystrophy represents a significant clinical milestone that could drive near-term revenue growth if approved, making this a pivotal moment for shareholders.
Mar 12
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
This boilerplate disclaimer suggests CAPR disclosed material information but provided minimal specifics, leaving investors unable to assess fundamental impacts on valuation or business operations.
Mar 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 2,027,732 | $62M | New | Mar 2026 |
| 2 | Tang Capital Management Llc | 1,700,000 | $49M | New | Dec 2025 |
| 3 | Morgan Stanley | 1,171,680 | $34M | Added | Dec 2025 |
| 4 | Jones Hill Capital Lp | 909,207 | $28M | New | Mar 2026 |
| 5 | Point72 Asset Management | 821,179 | $25M | Reduced | Mar 2026 |
| 6 | Fmr Llc | 772,649 | $23M | Reduced | Mar 2026 |
| 7 | Citadel Advisors Llc | 539,232 | $16M | Reduced | Mar 2026 |
| 8 | Northern Trust Corp | 417,543 | $13M | Added | Mar 2026 |
| 9 | Bank Of America Corp /de/ | 415,483 | $13M | Added | Mar 2026 |
| 10 | Dg Capital Management, Llc | 392,096 | $12M | Reduced | Mar 2026 |
| 11 | Vanguard Portfolio Management Llc | 379,214 | $12M | New | Mar 2026 |
| 12 | Ubs Group Ag | 371,984 | $11M | Added | Mar 2026 |
| 13 | Millennium Management | 356,354 | $11M | Reduced | Mar 2026 |
| 14 | Walleye Capital Llc | 355,086 | $11M | New | Mar 2026 |
| 15 | Barclays Plc | 314,792 | $10M | Added | Mar 2026 |
| 16 | Jpmorgan Chase & Co | 343,613 | $10M | Reduced | Mar 2026 |
| 17 | Rtw Investments, Lp | 250,000 | $8M | — | Mar 2026 |
| 18 | Raymond James Financial Inc | 196,300 | $6M | — | Mar 2026 |
| 19 | Invesco Ltd. | 185,372 | $6M | Added | Mar 2026 |
| 20 | Nuveen, Llc | 162,906 | $5M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.36B
Enterprise Value
$1.05B
P/E (TTM)
-12.65x
Forward P/E
—
PEG Ratio
-0.13x
P/B
4.46x
P/S
—
P/FCF
-0.02x
EV/EBITDA
1.17x
Shares Out
46.5M
Financials (TTM)
Revenue
$0
Net Income
-$114.6M
EBITDA
$893.3M
Free Cash Flow
-$72.72B
Op Cash Flow
-$69.81B
EPS Basic
$-2.26
EPS Diluted
$-2.32
EPS Forward
$-0.03
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$355.9M
Total Liab.
$50.2M
Total Equity
$305.8M
Cash
$318.1M
LT Debt
$0
Book Value/Sh
$6.58
Debt/Equity
0.07x
Current Ratio
9.01
Quick Ratio
9.01
Returns & Growth
ROE
-34.4%
ROA
-29.5%
ROIC
-33.1%
Rev Growth YoY
-100.0%
EPS Growth YoY
-96.5%
Price Returns
2W
+0.5%
1M
-10.8%
3M
+7.3%
6M
+460.0%
12M
+202.9%
Technicals
52W High
$35.34
52W Low
$4.60
50d MA
$30.54
200d MA
$21.50
RSI (14)
53.90
ATR (14)
$1.32
Beta
0.48
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$47.75
High
$62.00
Low
$13.00
Median
$50.00
Data updated apr 24, 2026 11:49pm
· Source: financialmodelingprep.com